Following the installation of a Corporate Scientific Advisory Board
in June 2007, DSM has now decided to establish a Biomedical
Scientific Advisory Board to support the company in its ambitions to
become a world leader in biomedical materials. The Biomedical
Scientific Advisory Board will consist of renowned opinion leaders in
the sciences and clinical disciplines that DSM Biomedical focuses on.
The first appointed members include Professor Tony Mikos (Rice
University, Houston, USA) who will head up the Biomedical Scientific
Advisory Board. He is an expert in the synthesis, processing and
application development of new biomaterials and has (co)authored over
330 publications. Furthermore Dr. Ivo Buschmann (Charité, University
of Medicine, Berlin and Freiburg University, Germany), and Mr.
Patrick Cahalan, BSc (Ension Inc., Pittsburgh, USA) have been
appointed. Dr. Buschmann is an Assistant Professor and clinical
cardiologist and an expert in cardiovascular research. He heads an
international research consortium called Art.Net. which focuses on
experimental and clinical research in the field of vascular biology
and arteriogenesis (collateral artery growth). Mr. Patrick Cahalan is
a medical device industry veteran. He has over three decades of R&D
experience, particularly in medical coatings, and holds more than 40
granted and pending patents.
Together with the other members, to be appointed in due course, these
experts will provide advice to DSM Biomedical on its research and
development strategy and program. The advice will include an
assessment of R&D programs and projects vis-à-vis scientific and
technological quality, validity of hypotheses, and clinical
relevance.
Steve Hartig, Vice President DSM Biomedical: "I am convinced that
early validation by external thought leaders of our ideas and
inventions on scientific merit and relevance will considerably
increase the success rate of our biomedical innovations. We are
honored that such leading experts as Tony Mikos, Patrick Cahalan and
Ivo Buschmann have committed themselves to our Board."
About DSM Biomedical
To meet the upcoming needs of the medical and biotech industries, DSM
Biomedical builds on the expertise and strengths of DSM in polymers,
coating technology, materials science and life sciences. DSM's
current biomedical portfolio includes hydrophilic coating technology
for catheters, guidewires and stent delivery systems and Dyneema
Purity®, a specially developed, high performance polyethylene fiber
technology, which is used in medical applications where maximum
strength and minimum weight are required. Furthermore DSM Biomedical
is focusing on developing materials and systems around implantable
devices for the musculoskeletal and vascular systems and drug
delivery devices in musculoskeletal, vascular and ophthalmic
application areas. For more information, visit
www.dsmbiomedical.com.
About DSM
DSM is active worldwide in nutritional and pharma ingredients,
performance materials and industrial chemicals. The company develops,
produces and sells innovative products and services that help improve
the quality of life. DSM's products are used in a wide range of
end-markets and applications, such as human and animal nutrition and
health, personal care, pharmaceuticals, automotive and transport,
coatings and paint, housing and electrics & electronics (E&E). DSM's
strategy, named Vision 2010 - Building on Strengths, focuses on
accelerating profitable and innovative growth of the company's
specialties portfolio. The key drivers of this strategy are
market-driven growth and innovation plus an increased presence in
emerging economies. The group has annual sales of over ¤8 billion and
employs some 22,000 people worldwide. DSM ranks among the global
leaders in many of its fields. The company is headquartered in the
Netherlands, with locations in Europe, Asia, Africa, Australia and
the Americas. More information about DSM can be found at www.dsm.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Elvira Luykx Dries Ausems
tel. +31 (0) 45 tel. +31 (0) 45 5782864
5782035 fax +31 (0) 45 5782595
fax +31 (0) 45 e-mail
5740680 investor.relations@dsm.com
e-mail media.relations@dsm.com